Here at Lipid Sciences we are extremely excited about the prospects for our unique, patented delipidation process. On this page we've gathered several articles that mention Lipid Sciences' HDL Therapy and you can see for yourself what others have been saying about it.

Articles Mentioning Lipid Sciences

Biotech Transfer Week: Unconventional IP Deal With Lipid Sciences Enables CHOP to Track, Tweak Tech Progress
Lipid Sciences licenses a cell-based assay technology from The Children's Hospital of Philadelphia to help it validate cardiovascular disease treatments as it readies them for regulatory approval.
Biotech Transfer Week, Volume 1, Issue No. 9, Apr. 30, 2007

Medscape: Raising High-Density Lipoprotein Cholesterol: What Are We Learning From the Torcetrapib Experience?
Perspective on the current state of HDL Therapy and its future potential.
Medscape, Mar. 20, 2007

USA Today: Next Frontier in Heart Disease
USA Today calls Lipid Sciences' delipidation technology part of the new frontier in the fight against heart disease.
USA Today, Jan. 8, 2006

Forbes: The Myth of Extra Virgin
Lipid Sciences' delipidation technology is used in non-human primate studies.
Forbes, Volume 174, Issue 12, Dec. 13, 2004

Forbes: The Cleaner
Lipid Sciences is among those with a "radical approach" to treating atherosclerosis.
Forbes.com, Nov. 24, 2003

BusinessWeek Online: Good News About Good Cholesterol
Lipid Sciences is mentioned as one of the companies exploring techniques to "enhance HDL's effectiveness."
BusinessWeek Online, Jul. 25, 2003